RxDoctor Payments Data

Gregory Oldford, MD

Urology · West Bloomfield, MINPI 1376508762

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,095 of the $28,437 with a category attached, or 63.6%. Astellas Pharma US Inc accounts for 71.4% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $17,214 and has fallen 87.7% since, to $2,125 in 2025. Among urology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,437in general payments, 2019–2025

Across 488 payments — averaging $58.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$20K
  • Sumitomo Pharma America, Inc.$962
  • Antares Pharma, Inc.$855
  • Pfizer$702
  • AbbVie$601
  • Myriad Genetic Laboratories, Inc.$517
  • plus $4K from 41 others

What the payments were for

  • Speaking & faculty fees$18,09564%
  • Travel & lodging$3771%
  • Food & beverage$9,47333%
  • Education$4922%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,437 in reported general payments places this provider in the 90th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$620,172
Medicare patients
1,251
Services billed
16,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron398$359,156
MyrbetriqMirabegron337$346,496
XtandiEnzalutamide11$156,803
Mirabegron ErMirabegron125$77,970
Abiraterone Acetate15$50,742
Tamsulosin Hcl1,514$27,877
Methenamine Hippurate351$24,761
XyostedTestosterone Enanthate30$18,047
Finasteride958$17,827
Silodosin81$9,328
Potassium Citrate ErPotassium Citrate58$9,120
Tolterodine Tartrate ErTolterodine Tartrate62$7,584
Solifenacin Succinate143$6,400
Dutasteride105$5,070
Alfuzosin Hcl ErAlfuzosin Hcl162$4,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Xtandi$20,310$503,299348 claims
Sumitomo Pharma America, Inc.Gemtesa$962$359,156398 claims
Antares Pharma, Inc.Xyosted$855$18,04730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 urology providers in Michigan.

Other urology in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →